Professor Robert Smith, a pivotal figure in British pharmacology, has died at the age of 92. His extensive career, primarily at St Mary's medical school in London – now integrated into Imperial College – significantly advanced the understanding of why individuals respond differently to pharmaceutical drugs.
Smith's research focused on the complex interplay of genetic, biochemical, and clinical factors that dictate drug efficacy and side effects. His contributions helped to lay foundational knowledge for personalised medicine, an approach that tailors medical treatment to each patient's unique characteristics.
A notable achievement in his career was his involvement in the discovery of "debrisoquine polymorphism" in 1975. This breakthrough identified a genetic variation affecting how individuals metabolise the drug debrisoquine, a finding that had broader implications for understanding drug metabolism across a spectrum of medications. Smith was known for his enthusiastic participation in self-experimentation, a hands-on approach that underscored his dedication to scientific discovery.
His work at St Mary's positioned the institution at the forefront of pharmacological research. The insights gained from his studies have continued to influence drug development, prescription practices, and the understanding of adverse drug reactions, contributing to safer and more effective treatments for patients across the UK and globally.
The legacy of Professor Smith's research endures in current pharmaceutical science, particularly in the field of pharmacogenomics, which explores how genes affect a person's response to drugs. His pioneering efforts helped to shift the paradigm from a 'one-size-fits-all' approach to a more nuanced understanding of individual variability in drug response.